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A B S T R A C T
The Cu(I) alkyne azide click reaction of 17α-ethynylestradiol and di-tert-butyl (2-azidopropane-1,3-diyl)di-
carbamate afforded the novel 1,4 disubstituted 1,2,3 triazole and estrogen-based ligand 2-(4-(estradiol)-1H-
1,2,3-triazol-1-yl)propane-1,3-diamine, EDiolDap. Reaction of EDiolDap with Pt(II) DMSO precursors, cis-
[PtCl2(DMSO)2] and cis-[Pt(CBDCA)(DMSO)2] gave the corresponding Pt(II) estrogen linked complexes
[PtCl2(EDiolDap)] and [Pt(CBDCA)(EDiolDap)] respectively in good yield. Both Pt(II) estrogen linked complexes
exhibited superior activity as compared to cisplatin and carboplatin in 2D culture and exhibited ca. 30 fold
higher activity, in terms of IC50 values, against ER+ cancer cells (cervical, breast and ovarian) as compared to
the reference ER− colon cancer line. [PtCl2(EDiolDap)] and [Pt(CBDCA)(EDiolDap)] retained their anti-tumour
activity in an ovarian 3D spheroid culture model and reduced the viability of ovarian cancer cell spheroids ca. 9-
fold and 5-fold better, respectively, as compared to cisplatin.
1. Introduction
Cisplatin (Fig. 1) was approved by the US Food and Drug Admin-
istration for the treatment of testicular and ovarian cancers in De-
cember 1978 [1], thanks to Barnet Rosenberg and his team’s com-
mendable scientific curiosity and endeavour. Subsequently over
40 years of concerted and systematic effort have culminated in the
approval of two additional Pt-based drugs worldwide (carboplatin and
oxaliplatin, Fig. 1) and four nationally (heptaplatin, lobaplatin, mir-
iplatin, and nedaplatin) [2] together with the vast array of unrealised
Pt-based drug candidates reported in the literature.
The cytotoxicity of Pt anticancer drugs is primarily associated with
the ability of their electrophilic Pt(II) centres to covalently bind to
nuclear DNA. The resulting DNA adducts are believed to generate DNA
damage responses and ultimately induce apoptosis [3,4]. More recently
interest has grown in the non-nuclear effects of Pt based drugs given Pt
(II) centres also react with cytoplasmic nucleophiles, including mi-
tochondrial DNA, RNA and multiple mitochondrial and extra-
mitochondrial proteins [5,6]. Remarkably, oxaliplatin, which is usually
used clinically as part of a regimen with folinic acid and 5-fluorouracil
to treat stage III colorectal cancer, has been shown to induce im-
munogenic cell death and ribosome biogenesis stress related cell death
[7–9].
Efforts to curtail the side effects of and vanquish resistance (intrinsic
and acquired) to Pt-based anticancer chemotherapeutics continue to
drive research focussed on the development of novel Pt-based drug
candidates.
Numerous classes of Pt(II) and Pt(IV)-based drug candidates have
been specifically designed to target cancers, primarily by conjugating
biomolecules that have high binding affinities for receptors prevalent in
the desired tissue type [10].
The activity of estrogen, the primary female sex hormone, is
mediated by the presence of estrogen receptors (ERs) in cells. ERs are
over-expressed in breast, ovarian, colon and prostate cancers, which are
termed ER+. ERs therefore represent interesting anticancer targets. In
turn a host of strategies have been employed to date where derivatives
of one of the three major endogenous estrogens (estrone, estradiol, and
estriol) have been chemically linked to for example anticancer drug
molecules [10,11], radiopharmaceuticals [12] and fluorescent probes
[13] amongst others.
Numerous Pt steroid linked complexes have been developed to date
where steroids or their derivatives are bonded to either a mono-, di- or
tridentate amino carrier ligand or a labile dicarboxylato ligand,
Fig. 2[10,11,14].
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Many of the Pt estrogen-linked complexes described in the literature
display good ER binding affinity and have exhibited superior in vitro
cytotoxicity than cisplatin for example in ER+ cell lines such as the
MCF-7 breast cancer cell line, though not in ER- cell lines [10,11,14].
We are interested in the functionalisation of Pt based complexes
[19,20] and more recently in the development of click-based conjuga-
tion strategies [21,22]. The Cu(I) catalysed azide–alkyne cycloaddition
(CuAAC), Fig. 3, which generates the corresponding 1,4-disubstituted
1,2,3-triazole with excellent selectivity and in high yield, is synon-
ymous with ‘click chemistry’. To the best of our knowledge there are no
examples in the literature where click chemistry is employed to develop
a steroid linked ligand for an anticancer Pt drug candidate.
We describe within the synthesis, characterisation and in vitro an-
titumour potential of novel dichlorido and cyclobutanedicarboxylato Pt
(II) estrogen linked complexes both in 2D and 3D cell culture models of
ER+ and ER- cancer cells.
2. Experimental
2.1. Materials
All commercially available reagents and solvents were purchased
from Sigma Aldrich and used as supplied (Sigma Aldrich Ireland Ltd.,
Arklow, Co Wicklow) unless stated otherwise. Sodium azide and 17α-
ethynylestradiol were sourced from TCI chemicals (Tokyo Chemical
Industry UK Ltd., Oxford, UK) and K2PtCl4 was sourced from Alfa
Chemicals (Alfa Chemicals Ltd, Binfield, Bracknell, UK). Di-tert-butyl
(2-azidopropane-1,3-diyl)dicarbamate [23], cis-[Pt(CBDCA)(DMSO)2]
[24] and cis-[PtCl2(DMSO)2] [25] were synthesized as previously re-
ported.
2.2. Synthetic methods
Infrared spectroscopy (IR) measurements were obtained using a
Nicolet iS10 FT-IR (Thermo Fisher Scientific, Waltham, Massachusetts,
USA). The infrared spectra were recorded from 400 to 4000 wave-
numbers (cm−1) and analysed using OMNIC™ software (ver. 9.6,
Thermo Fisher Sceintific). 1H NMR spectra were recorded on a Bruker
Avance 400 NMR spectrometer. The spectra were analysed using
MestReNova software. The residual undeuterated solvent signals were
used as an internal reference [26]. 195Pt NMR spectra were recorded on
a Bruker 500 AR spectrometer and K2PtCl6 in D2O was used as an ex-
ternal standard. Mass spectrometry experiments were performed on an
Advion Expression Compact Mass Spectrometer where 10 μL of the
samples were injected in 300 μL of methanol:water:formic acid (90:9:1
v/v). The mass spectrometry data were acquired both in positive and
negative ion modes and the spectra analysed using the Advion Mass
Express software programme.
Elemental analysis (C, H, N and Cl) was performed at the
Microanalytical Laboratory, School of Chemistry and Chemical Biology,
University College Dublin, Ireland.
2.3. Syntheses
2.3.1. Synthesis of di-tert-butyl (2-(4-(estradiol)-1H-1,2,3-triazol-1-yl)
propane-1,3-diyl)dicarbamate 1
17α-Ethynylestradiol (0.400 g, 1.349mmol) and di-tert-butyl (2-
azidopropane-1,3-diyl)dicarbamate (0.425 g, 1.349mmol) were dis-
solved in 4:1 H2O:MeOH (50mL). CuSO4·5H2O (0.034 g, 0.135mmol)
and sodium ascorbate (0.534 g, 2.698mmol) in water (10mL) were
added and the reaction was stirred for 2 days at 40 °C. The reaction was
quenched with saturated ammonium chloride (40mL) and extracted
into EtOAC (3× 70mL). The organic layer was washed with brine
(70mL), dried over Na2SO4, filtered and concentrated under reduced
pressure. The crude product was subject to column chromatography on
silica using 9:1 DCM:MeOH to yield 1 as a yellow crystalline solid
(800mg, 97%).
1H NMR (400MHz, CDCl3) δ: 7.65 (bs, 1H), 6.98 (bs, 1H), 6.56 (m,
2H), 5.58 (m, 2H), 4.65 (m, 1H), 3.78 (m, 2H), 3.54 (m, 2H), 3.17 (m,
1H), 2.74 (m, 2H), 2.35 (m, 3J=18.3 Hz, 1H), 2.09 (m, 1H), 1.88 (m,
J=12.6 Hz, 3H), 1.55 (m, J=28.2 Hz, 3H), 1.42 (bs, J=4.2 Hz,
22H), 1.02 (s, 3H), 0.60 (m, 1H) ppm. 13C NMR (101MHz, CDCl3) δ:
207.5, 156.7, 153.9, 138.2, 132.1, 126.4, 115.5, 113.0, 80.3, 60.6,
53.6, 48.6, 43.3, 41.3, 41.1, 39.5, 33.1, 31.1, 29.8, 28.4, 27.4, 26.3,
23.6, 21.2, 14.3 ppm. (ESI+ ) m/z: 612.5 ([M+H]+), 634.5.
([M+Na]+).
2.3.2. Synthesis of 2-(4-(estradiol)-1H-1,2,3-triazol-1-yl)propane-1,3-
diamine dihydrochloride 2
6M HCl (5mL) was added to 1 (0.800 g, 1.31mmol) dissolved in
EtOAc (5mL). The solution was stirred at rt for 2 h and stored at −18 °C
for 4 h. The resultant white precipitate was vacuum filtered and washed
with EtOAc to yield 2 as a white solid (0.604 g, 95%).
1H NMR (400MHz, D2O) δ: 8.06 (s, 1H), 7.12 (d, 3J=8.2 Hz, 1H),
6.61 (d, 3J=8.2 Hz, 2H), 5.29 (td, 3J=9.1, 4J= 4.4 Hz, 1H), 3.72
(ddd, 3J=13.2, 4J=9.3, 3.6 Hz, 2H), 3.63 (dd, 3J=13.5, 4J=3.7 Hz,
2H), 2.74 (d, 3J=5.6 Hz, 2H), 2.43 – 2.32 (m, 1H), 2.17 – 2.05 (m,
1H), 1.95 – 1.81 (m, 3H), 1.66 – 1.48 (m, 3H), 1.47 – 1.32 (m, 2H), 1.32
– 1.11 (m, 2H), 0.97 (s, 3H), 0.78 (t, 3J=12.7, 4J=9.0 Hz, 1H) ppm.
13C NMR (101MHz, D2O) δ: 154.4, 153.2, 138.9, 132.6, 126.7, 124.0,
115.3, 112.9, 82.7, 56.6, 47.9, 46.9, 42.7, 40.7, 40.6, 38.9, 36.7, 32.2,
28.9, 26.8, 25.6, 22.9, 13.7 ppm. (ESI+) m/z: ([M−2Cl]) 413.5.
2.3.3. Synthesis of [PtCl2(EDiolDap)] 3
DBU (70.9 µL, 0.474mmol) was added to 2 (0.114 g, 0.237mmol)
dissolved in DMF (1mL). The resultant solution was added dropwise to
cis-[PtCl2(DMSO)2] (0.100 g, 0.237mmol) dissolved in DMF (1mL).
The reaction was stirred at rt for 2 days. Water (3mL) was added to the
flask resulting in the precipitation of an off white solid. The solution
was cooled to 4 °C for 4 h. The precipitate was vacuum filtered and
washed with water and Et2O and dried over P2O5 to give 4 as a brown
solid (92.9mg, 58%). EA calc. % for C23H33Cl2N5O2Pt·0.25H2O requires
C, 40.50; H, 4.95; N, 10.27; Cl, 10.40, found C, 40.71; H, 5.32; N, 10.41;
Cl 10.17%. 1H NMR (400MHz, DMF-d7) δ: 9.17 (s, 1H), 8.12 (s, 1H),
7.02 (d, 3J=12Hz, 1H), 6.58 (d, J=12Hz, 1H), 6.55 (s, 1H), 5.60 (bs,
2H), 5.51 (bs, 2H), 5.16 (s, 1H), 5.07 (t, 3J=8Hz, 1H), 3.58 (m, 1H),
3.33 (m, 2H), 3.08 (d, 3J=8Hz, 2H), 2.41 (m, 1H), 2.05 (m, 3H), 1.73
(m, 6H), 1.25 (m, 6H), 0.67 (t, 3J=12Hz, 1H) ppm. 195Pt NMR
(86MHz, DMSO‑d6) δ: −2277.74 ppm. ESI-MS (+ve): m/z
(M−Cl+DMSO) 720.5. FT-IR νmax (cm−1): 3189, 3120, 2925, 2871,
1652, 1609, 1498, 1436, 1386, 1288, 1251, 1224, 1131, 1098, 1060,
1024, 913, 871, 819, 787, 661.
2.3.4. Synthesis of [Pt(CBDCA)(EDiolDap)] 4
NaOH (0.019 g, 0.480mmol) in water (5mL) was added to 2
(0.116 g, 0.240mmol) dissolved in DMF (1mL). The resultant solution
was added dropwise to cis-[Pt(CBDCA)(DMSO)2] (0.114 g, 0.240mmol)
dissolved in water (10mL) at 100 °C. The reaction was stirred at 100 °C
Fig. 1. Structures of (a) cisplatin (cis-[PtCl2(NH3)2]), (b) carboplatin ([Pt
(CBDCA)(NH3)2], CBDCA= cyclobutane-1,1-dicarboxylato) and (c) oxaliplatin
([Pt(DACH)(Ox)] (DACH=1R,2Rdiaminocyclohexane, Ox= oxalato).
E. Kitteringham, et al. Inorganica Chimica Acta 495 (2019) 118944
2
for 6 h. A precipitate was vacuum filtered and washed with water, EtOH
and Et2O to give 4 as a white solid (0.133 g, 74%). EA calc. % for
C29H39O6N5Pt·1.5H2O requires C, 44.90; H, 5.46; N, 9.03, found C,
44.75; H, 5.46; N, 9.12%. 1H NMR (400MHz, DMSO‑d6) δ: 8.99 (s, 1H),
7.98 (s, 1H), 6.95 (d, 3J=8.0 Hz, 1H), 6.45 (d, 3J=8.0 Hz, 2H), 5.48
(bs, 2H), 5.32 (bs, 2H), 5.20 (s, 1H), 4.58 (t, 3J=8.0 Hz, 1H), 2.90 (m,
2H), 2.68 (m, 3H), 2.31 (m, 2H), 2.24 (t, 3J=8Hz, 2H), 2.07 (m, 2H),
1.74 (m, 7H), 1.60 (m, 2H), 1.40 (m, 3H), 1.28 (m, 2H), 1.16 (m, 2H),
0.49 (t, 3J=8Hz, 1H) ppm. 195Pt NMR (86MHz, DMSO‑d6) δ:
−3245.61 ppm. ESI-MS(-ve): m/z (M−H) 747.0, (M−2xOH) 714.2.
FT-IR νmax (cm−1): 3384, 3195, 3116, 2932, 2870, 1648, 1609, 1585,
1500, 1448, 1378, 1356, 1289, 1235, 1153, 1053, 1022, 913, 870, 847,
787.
2.4. Biological studies
Pt(II) complexes, 3 and 4, were dissolved in minimum DMSO di-
rectly prior to testing. A calculated amount of the stock drug DMSO
solution was added to the cell culture medium to give a final maximum
DMSO concentration of 0.5%, which had no effects on cell viability.
Cisplatin and carboplatin were dissolved in 0.9% sodium chloride so-
lution. MTT (3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium
bromide), cisplatin, carboplatin and ImmunoPure p-nitrophenyl phos-
phate (APH) were obtained from Sigma Chemical Co, St. Louis, USA.
2.4.1. Cell cultures
Human colon (HCT-15) and breast (MCF-7) carcinoma cell lines
were obtained from American Type Culture Collection (ATCC,
Rockville, MD). Human ovarian 2008 cancer cells were kindly provided
by Prof. G. Marverti (Dept. of Biomedical Science of Modena University,
Italy). Human ovarian A2780 cancer cells were kindly provided by Prof.
M.P.Rigobello (Dept. of Biomedical Science of Padova University,
Italy). Human squamous cervical A431 carcinoma cells were kindly
provided by Prof. F. Zunino (Division of Experimental Oncology B,
Istituto Nazionale dei Tumori, Milan, Italy). Cell lines were maintained
in the logarithmic phase at 37 °C in a 5% carbon dioxide atmosphere
using RPMI-1640 medium (Euroclone) containing 10% foetal calf
serum (Euroclone, Milan, Italy), antibiotics (50 units/mL penicillin and
50 μg/mL streptomycin), and 2mM l-glutamine.
2.4.2. Spheroid cultures
Spheroids were initiated in liquid overlay by seeding 1.5× 103
A2780 cells/well in phenol red free RPMI-1640 medium (Sigma
Chemical Co.), containing 10% FCS and supplemented with 20% me-
thyl cellulose stock solution. A total of 150 μL of this cell suspension
was transferred to each well of a round bottom non-tissue culture
treated 96 well-plate (Greiner Bio-one, Kremsmünster, Austria) to allow
spheroid formation within 72 h.
2.4.3. Cytotoxicity assays
2.4.3.1. MTT assay. The growth inhibitory effect towards adherent
cancer cell lines was evaluated by means of MTT assay [27]. Briefly,
3–8×103 cells/well, dependent upon the growth characteristics of the
cell line, were seeded in 96-well microplates in growth medium
(100 μL). After 24 h, the medium was removed and replaced with
fresh media containing the compound to be studied at the appropriate
concentration. Triplicate cultures were established for each treatment.
After 72 h, each well was treated with 10 μL of a 5mg/mL MTT saline
solution, and after additional 5 h of incubation, 100 μL of a sodium
dodecylsulfate (SDS) solution in HCl 0.01M were added. Following an
overnight incubation, cell growth inhibition was detected by measuring
the absorbance of each well at 570 nm using a Bio-Rad 680 microplate
reader. Mean absorbance for each drug dose was expressed as a
percentage of the absorbance of the untreated control well and
plotted vs drug concentration. IC50 values, the drug concentrations
that reduce the mean absorbance at 570 nm to 50% of those in the
untreated control wells, were calculated by four parameters logistic (4-
Fig. 2. Representative examples of Pt(II) and Pt(IV) steroid linked complexes; (a) estrogen [15], (b) testosterone [16], (c) cortisone [11], (d) cholic acid [17], and (e)
estrogen [18].
Fig. 3. Copper(I) catalysed azide alkyne 1,3-dipolar cycloaddition reaction
between azides and terminal alkynes.
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PL) model. All the values are the means ± SD of not less than five
measurements starting from three different cell cultures.
2.4.3.2. Acid phosphatase (APH) assay. An APH modified assay was
used for determining cell viability in 3D spheroids. Briefly, the pre-
seeded spheroids were treated with fresh medium containing the
compound to be studied at the appropriate concentration. Triplicate
cultures were established for each treatment. After 72 h, each well was
treated with 100 μL of the assay buffer (0.1M sodium acetate, 0.1%
Triton-X-100, supplemented with ImmunoPure p-nitrophenyl
phosphate) and, following 3 h of incubation, 10 μL of 1M NaOH
solution were added. The inhibition of the cell growth induced by the
tested complexes was detected by measuring the absorbance of each
well at 405 nm, using a Bio-Rad 680 microplate reader. Mean
absorbance for each drug dose was expressed as a percentage of the
untreated control well absorbance (T/C) and plotted vs drug
concentration. IC50 values, the drug concentrations that reduce the
mean absorbance at 405 nm 50% of those in the untreated control
wells, were calculated by four parameter logistic (4-PL) model.
Evaluation was based on means from at least four independent
experiments.
3. Results and discussion
3.1. Synthesis of 2-(4-(estradiol)-1H-1,2,3-triazol-1-yl)propane-1,3-
diamine dihydrochloride 2
(2-(4-(estradiol)-1H-1,2,3-triazol-1-yl)propane-1,3-diamine) dihy-
drochloride 2 was synthesised in two steps, Scheme 1, in line with
previous reports [21–23].
In the first step, the CuAAC reaction of 17α-ethynylestradiol and di-
tert-butyl (2-azidopropane-1,3-diyl)dicarbamate gave the corre-
sponding 1,4 disubstituted 1,2,3 triazole, di-tert-butyl (2-(4-(estradiol)-
1H-1,2,3-triazol-1-yl)propane-1,3-diyl)dicarbamate 1, in 97% yield. 1
was characterised by 1H and 13C NMR spectroscopy and mass spec-
trometry, Figs. S1-3, Supplementary Material.
In the 1H NMR spectrum for example key diagnostic signals include
those for the single triazole proton at 7.65 ppm and the eighteen tert-
butyl protons at 1.42 ppm. ESI-MS in positive mode revealed the pre-
sence of ions asscociated with M+H and M+Na at 612.5 and 634.5
a.m.u. respectively.
In the second step, standard BOC deprotection of the diamine
groups in 1 using HCl afforded the corresponding HCl salt, 2-(4-(es-
tradiol)-1H-1,2,3-triazol-1-yl)propane-1,3-diamine dihydrochloride 2
in 95% yield. 2 was characterised by 1H and 13C NMR spectroscopy and
mass spectrometry, Figs. S4–6, Supplementary Material. The 1H NMR
spectrum of 2 in D2O 15 signals are associated with 27 protons. Protons
associated with the two amine groups (6×H) and the two hydroxyl
protons are not present as expected. The single triazole proton is found
at 8.06 ppm. ESI-MS in positive mode aided the identification of the
M−2Cl product ion fragments at 413.5 a.m.u.
3.2. Synthesis of Pt estradiol complexes.
Pt(II) estradiol complexes were synthesised on neutralisation of 2-(4-
(estradiol)-1H-1,2,3-triazol-1-yl)propane-1,3-diamine dihydrochloride 2
with two equivalents of base and subsequent reaction with Pt(II) di-
methylsulfoxido precursor complexes [24,28].
Reaction of cis-[PtCl2(DMSO)2] with 2 in the presence of two
equivalents of 1,8-diazabiciclo[5.4.0]undek-7-en (DBU) afforded the
novel Pt(II) dichlorido estradiol complex, [PtCl2(EDiolDap)] 3 (Scheme
2) in moderate yield (58%), where EDiolDap is 2-(4-(estradiol)-1H-
1,2,3-triazol-1-yl)-propane-1,3-diamine. cis-[PtCl2(DMSO)2] for ex-
ample was previously employed as a precursor for the synthesis of
diamino platinum(II) complexes of formulae cis-[PtCl2(diamine)]
[28–30]. 3 was characterized by elemental analysis, 1H and 195Pt NMR
spectroscopy and mass spectrometry, Figs. S7–10, Supplementary
Material.
Elemental analysis of 3 is consistent with two chlorido ligands and
one EDiolDap ligand per Pt(II) centre. In the 1H NMR spectrum diag-
nostic signals for example comprise the triazole proton at 9.17 ppm, the
three aromatic protons at 8.12, 7.02 and 6.58 ppm and the four amino
protons observed at 5.60 and 5.51 ppm as two broad singlets. The re-
maining twenty five aliphatic protons are accounted for in the complex
spectrum, Fig. S7, Supplementary Material. The 195Pt NMR features one
signal at −2277 ppm, which is consistent with a Pt(II)N2Cl2 type
complex. The ESI MS in positive mode, obtained from a DMSO solution
of 3 diluted with MeOH, features a mass at 720.5 a.m.u associated with
[PtCl(DMSO)(EDiolDap)]+ and the expected Pt isotopic pattern.
Reaction of cis-[Pt(CBDCA)(DMSO)2] with 2 in the presence of two
equivalents of NaOH afforded the novel Pt(II) 1,1-cyclobutanedi-
carboxylato estradiol complex, [Pt(CBDCA)(EDiolDap)] 4 in good yield
(74%). cis-[Pt(CBDCA)(DMSO)2] for example was previously employed
as a precursor for the synthesis of diamino platinum(II) complexes of
formulae cis-[Pt(CBDCA)(diamine)] [24,28,30]. 4 was characterized by
elemental analysis, 1H and 195Pt NMR and mass spectrometry. Ele-
mental analysis of 4 is consistent with one 1,1-cyclobutanedicarbox-
ylato ligand and one EDiolDap ligand per Pt(II) centre.
In the 1H NMR spectrum diagnostic signals for example consist of
the triazole proton at 8.99 ppm, the three aromatic protons at 7.98,
6.95 and 6.45 ppm and the four amino protons at 5.48 and 5.32 ppm as
two broad singlets. The remaining thirty one aliphatic protons are
Scheme 1. CuAAC synthesis of di-tert-butyl (2-(4-(estradiol)-1H-1,2,3-triazol-1-yl)propane-1,3-diyl)dicarbamate 1 and HCl deprotection of 1 to 2-(4-(estradiol)-1H-
1,2,3-triazol-1-yl)propane-1,3-diamine dihydrochloride 2.
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accounted for in the complex spectrum, Fig. S11, Supplementary
Material. The 195Pt NMR features one signal at −3245.61 ppm, which is
consistent with a Pt(II)N2O2 type complex. The ESI MS in negative
mode features masses at 747.0 a.m.u associated with M−H and 714.2
associated with M−2xOH. The expected Pt isotopic pattern is observed.
3.3. Cytotoxic activity in 2D and 3D cancer cell cultures
With the aim of evaluating if the newly developed Pt(II) complexes
3 and 4 are more effective in targeting and affecting the viability of ER
+ cell lines with respect to ER- ones, their in vitro antitumour potential
was assessed in a panel of ER+ human cancer cell lines; A431 (cer-
vical), MCF-7 (breast), and 2008 and A2780 (ovarian) cancer cells as
well as against ER- HCT-15 colon cancer cells. Cells were exposed to the
indicated compounds for 72 h and the IC50 values, calculated from the
dose–response curves, are listed in Table 1.
Both complexes exhibited impressive in vitro cytotoxic activity, su-
perior than those elicited by reference Pt(II) compounds cisplatin and
carboplatin, with IC50 values in the low-/sub-micromolar range against
all cancer cell lines tested. Compound 3 elicited average IC50 values of
0.035 μM, up to one order of magnitude higher with respect to complex
4. Remarkably, the IC50 for [PtCl2(EDiolDap)] (0.01 μM) against the
commonly studied MCF-7 cancer cell line, is remarkably lower than the
IC50 values associated with previously reported classes of Pt(II) estra-
diol-linked complexes; 2–4 μM[31], 3–33 μM[32] and > 3 μM[33], for
example. Both complexes showed greater in vitro cytotoxic activity
against ER+ cancer cells, where the IC50 values calculated for both
derivatives against the ER- colon cancer line HCT-15 were about 30
times higher than those calculated against the in-house ER+ panel of
cancer cells. This data strongly support the ability of these estradiol-
bearing Pt(II) complexes to selectively target ER+ cancer cell lines.
The in vitro antitumour potential of Pt(II) complexes was also ex-
amined in a 3D ovarian cancer cell culture model. 3D spheroid models
are more physiologically relevant and predictive compared to 2D
models when screening potential anti-proliferative drug candidates.
Table 2 summarizes the IC50 values obtained after treatment of
A2780 cancer cell spheroids with the novel Pt(II) complexes, 3 and 4,
and cisplatin, the control Pt(II)-based anticancer drug.
In accordance with 2D tests, complex 3 proved to be the most ef-
fective compound, showing an efficacy in decreasing cancer spheroid
viability about 9 times higher than that of cisplatin. However, com-
plexes 4 despite being less effective than 3, it retained an antitumour
efficacy in 3D cell system which was about 5 times higher than that of
cisplatin.
4. Conclusion
Triazoles are ideally suited to build multifunctional ligand systems
given the high synthetic flexibility associated with click chemistry. The
estrogen based ligand 2-(4-(estradiol)-1H-1,2,3-triazol-1-yl)propane-
1,3-diamine, EDiolDap was synthesised in good yield by the CuAAC
reaction between 17α-ethynylestradiol and di-tert-butyl (2-azidopro-
pane-1,3-diyl)dicarbamate. Reaction of EDiolDap with Pt(II) DMSO
precursors, cis-[PtCl2(DMSO)2] and cis-[Pt(CBDCA)(DMSO)2] gave the
corresponding Pt(II) estrogen linked complexes [PtCl2(EDiolDap)] and
[Pt(CBDCA)(EDiolDap)] respectively in good yield. The in vitro cyto-
toxicity of both estrogen linked Pt(II) complexes and cisplatin were
investigated against a panel of ER+ cancer cell lines (cervical - A431,
breast - MCF-7 and ovarian − 2008 and A2780) as well as against an
ER- colon cancer cell line, HCT-15. Both complexes exhibited superior
in vitro cytoxicity than cisplatin against all of the cancer cell lines tested.
[PtCl2(EDiolDap)] exhibited approximately an order of magnitude
Scheme 2. Synthesis of [PtCl2(EDiolDap)] 3 and [Pt(CBDCA)(EDiolDap)] 4.
Table 1
In vitro cytotoxic activity. Cells (3–8×103 mL−1) were treated for 72 h with increasing concentrations of tested compounds. Cytotoxicity was assessed by MTT test.
IC50 values (μM) were calculated by a four parameter logistic model (P < 0.05). S.D.= standard deviation.
IC50 ± S.D.
A2780 2008 A431 MCF-7 HCT-15
3 0.01 ± 0.003 0.09 ± 0.01 0.03 ± 0.01 0.01 ± 0.004 0.4 ± 0.1
4 0.1 ± 0.02 0.7 ± 0.3 0.5 ± 0.1 0.3 ± 0.06 1.8 ± 0.4
Cisplatin 2.6 ± 0.8 2.2 ± 0.6 1.7 ± 0.3 7.6 ± 0.2 13.9 ± 1.7
Carboplatin 3.6 ± 1.2 5.8 ± 1.4 12.3 ± 3.3 >100 >100
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greater in vitro cytotoxic activity than its dicarboxylato analogue, [Pt
(CBDCA)(EDiolDap)]. Interestingly the two estrogen linked Pt(II)
complexes showed a ca. 30 times greater in vitro cytotoxic effect against
ER+ cancer cell lines as compared to against the ER- colon cancer line
HCT-15.
3D cell culture is superior to traditional 2D culture at simulating an
in vivo environment. It is therefore noteworthy that [PtCl2(EDiolDap)]
and [Pt(CBDCA)(EDiolDap)] retained their anti-tumour activity in an
ovarian 3D A2780 spheroid culture model and reduced the viability of
the ovarian cancer cell spheroids ca. 9 fold and 5 fold better respec-
tively as compared to the clinically used Pt-based chemotherapeutic,
cisplatin.
The functionalisation of Pt based complexes is an important strategy
for the development of the next generation of Pt-based anticancer
drugs. Though many Pt(II) steroid complexes have been developed to
date, this novel class certainly exhibits standout in vitro cytotoxic ac-
tivity.
5. Supplementary material
1H, 13C and 195Pt NMR and ESI mass spectra are available to view.
Acknowledgements
EK sincerely thanks the Royal College of Surgeons in Ireland for
financial support through the RCSI Apjohn Scholarship. This publica-
tion has emanated from research supported in part by a research grant
from Science Foundation Ireland (SFI) and is co-funded under the
European Regional Development Fund under Grant Number 12/RC/
2275_P2.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ica.2019.05.043.
References
[1] B. Lippert (Ed.), Cisplatin - Chemistry and Biochemistry of a Leading Anticancer
Drug, Wiley-VCH, Weinheim, 1999.
[2] R. Oun, Y.E. Moussa, N.J. Wheate, Dalton Trans. 47 (2018) 6645–6653.
[3] L. Kelland, Nat. Rev. 7 (2007) 573–584.
[4] N.J. Wheate, S. Walker, G.E. Craig, R. Oun, Dalton Trans. 39 (2010) 8113–8127.
[5] L. Galluzzi, I. Vitale, J. Michels, C. Brenner, G. Szabadkai, A. Harel-Bellan, M.
Castedo, G. Kroemer, Cell. Death Dis., vol. 5, 2014, pp. e1257.
[6] J.D. White, M.M. Haley, V.J. DeRose, Acc. Chem. Res. 49 (2016) 56–66.
[7] S. Göschl, E. Schreiber-Brynzak, V. Pichler, K. Cseh, P. Heffeter, U. Jungwirth,
M.A. Jakupec, W. Berger, B.K. Keppler, Metallomics 9 (2017) 309–322.
[8] P.M. Bruno, Y. Liu, G.Y. Park, J. Murai, C.E. Koch, T.J. Eisen, J.R. Pritchard,
Y. Pommier, S.J. Lippard, M.T. Hemann, Nat. Med. 23 (2017) 461–471.
[9] I.A. Riddell, Met. Ions,, Life Sci. vol, (2018) 18.
[10] R.G. Kenny, C.J. Marmion, Chem. Rev. 119 (2019) 1058–1137.
[11] F. Le Bideau, S. Dagorne, Chem. Rev. 113 (2013) (2013) 7793–7850.
[12] H.M. Linden, L.M. Peterson, A.M. Fowler, PET clinics 13 (2018) 415–422.
[13] N. Gajadeera, R.N. Hanson, Steroids 144 (2019) 30–46.
[14] P. Zhang, Y.W. Yang, Z.R. Shen, Mini Rev. Med. Chem. 13 (2013) 265–272.
[15] A. Jackson, J. Davis, R.J. Pither, A. Rodger, M.J. Hannon, Inorg Chem 40 (2001)
3964–3973.
[16] S. Fortin, K. Brasseur, N. Morin, E. Asselin, G. Berube, Eur. J. Med. Chem. 68 (2013)
433–443.
[17] R. Paschke, J. Kalbitz, C. Paetz, M. Luckner, T. Mueller, H.J. Schmoll, H. Mueller,
E. Sorkau, E. Sinn, J. Inorg. Biochem. 94 (2003) 335–342.
[18] K.R. Barnes, A. Kutikov, S.J. Lippard, Chem. Biol. 11 (2004) 557–564.
[19] A. McKeon, A. Egan, J. Chandanshive, H. McMahon, D. Griffith, Molecules, vol. 21,
2016, pp. 949.
[20] A.M. McKeon, J. Noonan, M. Devocelle, B.M. Murphy, D.M. Griffith, Chem.
Commun. 53 (2017) 11318–11321.
[21] E. Kitteringham, Z. Zhou, B. Twamley, D.M. Griffith, Inorg. Chem. 57 (2018)
12282–12290.
[22] E. Kitteringham, D. Wu, S. Cheung, B. Twamley, D.F. O'Shea, D.M. Griffith, J. Inorg.
Biochem. 182 (2018) 150–157.
[23] D. Urankar, J. Košmrlj, Inorg. Chim. Acta 363 (2010) 3817–3822.
[24] P. Bitha, G.O. Morton, T.S. Dunne, E.F. Delos Santos, Y.I. Lin, S.R. Boone, R.C.
Haltiwanger, C.G. Pierpont, Inorg. Chem., vol. 29, 1990, pp. 645-652.
[25] V.Y. Kukushkin, A.J.L. Pombeiro, C.M.P. Ferreira, L.I. Elding, Inorg. Synth. 33
(2002) 189–196.
[26] H.E. Gottlieb, V. Kotlyar, A. Nudelman, J. Org. Chem. 62 (1997) 7512–7515.
[27] M.C. Alley, D.A. Scudiero, A. Monks, M.L. Hursey, M.J. Czerwinski, D.L. Fine,
B.J. Abbott, J.G. Mayo, R.H. Shoemaker, M.R. Boyd, Cancer Res. 48 (1988)
589–601.
[28] J.J. Wilson, S.J. Lippard, Chem. Rev. 114 (2014) 4470–4495.
[29] B. Aljoša, U. Damijana, K. Janez, Eur. J. Org. Chem. 2014 (2014) 8167–8181.
[30] C. Cassino, E. Gabano, M. Ravera, G. Cravotto, G. Palmisano, A. Vessières,
G. Jaouen, S. Mundwiler, R. Alberto, D. Osella, Inorg. Chim. Acta 357 (2004)
2157–2166.
[31] C. Descôteaux, V. Leblanc, G. Bélanger, S. Parent, É. Asselin, G. Bérubé, Steroids 73
(2008) 1077–1089.
[32] P. Saha, C. Descôteaux, K. Brasseur, S. Fortin, V. Leblanc, S. Parent, É. Asselin,
G. Bérubé, Eur. J. Med. Chem. 48 (2012) 385–390.
[33] R. Schobert, G. Bernhardt, B. Biersack, S. Bollwein, M. Fallahi, A. Grotemeier, G.L.
Hammond, ChemMedChem, vol. 2, John Wiley & Sons, Ltd, 2007, pp. 333-342.
Table 2
In vitro cytotoxicity against ovarian cancer cell
spheroids. Spheroids (1.5× 103 cells/well) were
treated for 72 h with increasing concentrations of
test compounds. The growth inhibitory effect was
evaluated by means of the APH test. IC50 values
were calculated from the dose-survival curves by




3 12.4 ± 1.2
4 20.1 ± 3.5
Cisplatin 111.6 ± 7.5
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